GlassScriptPhysician profile
Paul M Imber
NPI 1245308147
$5,191.42
in general payments reported to CMS, 2019-2025
35 companies · $574 in 2025
The $574 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,401 · 2020: $66.29 · 2021: $194 · 2022: $572 · 2023: $497 · 2024: $888 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,958.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $2,182.11 | 2019 | |
| Biocryst US Sales Co., LLC | $625.73 | 2022-2025 | Orladeyo |
| Csl Behring | $480.00 | 2022-2025 | Hizentra, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $322.41 | 2021-2025 | Hyqvia, Glassia, Cuvitru |
| Optinose US, INC. | $213.83 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $185.98 | 2021-2024 | |
| Medtronic, INC. | $164.66 | 2025 | Propel |
| Kaleo, INC. | $129.62 | 2022-2024 | Auvi-Q |
| Glaxosmithkline, LLC. | $117.22 | 2021-2025 | Nucala |
| Stryker Corporation | $82.82 | 2019 | |
| Pharming Healthcare, INC. | $76.93 | 2022-2024 | Ruconest |
| Regeneron Healthcare Solutions, INC. | $57.60 | 2019-2020 | |
| Genzyme Corporation | $57.58 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $48.31 | 2022-2023 | Airduo Digihaler |
| Grifols USA, LLC | $36.66 | 2024 | Xembify |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $35.03 | 2025 | |
| Aimmune Therapeutics, INC. | $33.56 | 2021-2022 | |
| Alk-Abello, INC | $32.15 | 2022 | |
| Amgen INC. | $29.88 | 2022 | |
| Incyte Corporation | $27.04 | 2025 | Opzelura |
| Bio Products Laboratory USA, INC. | $25.60 | 2022 | |
| Upsher-Smith Laboratories LLC | $24.15 | 2021 | |
| Paratek Pharmaceuticals, INC. | $23.57 | 2025 | Xhance |
| Blueprint Medicines Corporation | $23.13 | 2024 | Ayvakit |
| Octapharma USA, INC. | $20.83 | 2023 | Cutaquig |
| Leo Pharma INC. | $19.51 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.70 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $15.80 | 2025 | Neffy |
| Neos Therapeutics, LP | $13.78 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.03 | 2022 | |
| Hikma Pharmaceuticals USA | $12.80 | 2023 | Ryaltris |
| Biohaven Pharmaceuticals, INC. | $12.02 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.43 | 2021 | |
| Glenmark Therapeutics INC. | $11.00 | 2019 | |
| Phathom Pharmaceuticals, INC. | $6.95 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Imber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.